Other NIH Programs for Translational Neuroscience

The HEAL Pain Therapeutics Development Program (PTDP)

The PTDP is a part of the Helping to End Addiction Long-term® (HEAL) Initiative ®,a trans-NIH research effort focused on improving prevention and treatment for opioid misuse and addiction and enhancing pain management. The PTDP supports preclinical optimization and development of safe, effective, and non-addictive small molecule and biologic therapeutics to treat pain. This is a milestone-driven phased cooperative agreement grant involving participation of NIH program staff and consultants in the development of the project plan and monitoring of research progress.

Funding for High Throughput Screening

Preclinical Screening Platform for Pain (PSPP)

• Support: Within the NIH HEAL Initiative, NINDS created the Preclinical Screening Platform for Pain (PSPP) to identify and profile non-addictive therapeutics (small molecules, biologics, devices, or natural products) for acute and chronic pain.
• Participating Institutes: FIC, NCI, NCATS, NCCIH, NEI, NHLBI, NIA, NIAAA, NIBIB, NIDCR, NIDDK, NIDA, NINDS
• To apply: contact Program Director, Smriti Iyengar, smriti.iyengar@nih.gov

IGNITE: Assay Development and Neurotherapeutic Agent Identification

• Support: 3-year R61/R33 support assay development and neurotherapeutic agent identification
• Participating Institutes: NINDS, NCCIH
• To apply: PAR-21-124

Funding for Medicinal Chemistry (Hit-to-Lead)

Solicitation of Validated Hits for the Discovery of in vivo Chemical Probes

• Support: 3-year R01s to improve probes for in vivo proof-of-concept studies
• Participating Institutes: NIMH, NEI, NIA, NIDA
• To apply: PAR-21-029

Funding for Preclinical Proof-of-Concept

Drug Discovery for Nervous System Disorders

• Support: Up to 5 years (R01) or 2 years (R21) of funding to support the discovery of novel compounds for the prevention and treatment of nervous system disorders.
• Participating Institutes: NIMH, NIA, NIAAA, NIDA
• To apply: PAR-19-147 (R01), PAR-19-146 (R21)

IGNITE: Neurotherapeutic Agent Characterization and In vivo Efficacy Studies

• Support: 3-year R61/R33 support Neurotherapeutic Agent Characterization and In vivo Efficacy Studies
• Participating Institute: NINDS
• To apply: PAR-21-122

Funding for Translational Model Development

IGNITE: Development and Validation of Model Systems to Facilitate Neurotherapeutic Discovery (R61/R33 Clinical Trial Not Allowed)

• Support: 3- year R61/R33 to support Development and Validation of Model Systems and/or Pharmacodynamic Markers to Facilitate Neurotherapeutic Discovery
• Participating Institute: NINDS
• To apply: PAR-21-123

Funding for Preclinical/Clinical Development

National Cooperative Drug Discovery/Development Groups (NCDDG)

• Support: Up to 5 years of funding for multidisciplinary teams, Public Private Partnerships
• Participating Institutes: NIMH, NIAAA
• To apply: PAR-22-143 (U01), PAR-22-144 (U19)

Regulatory Affairs Assistance for Medications Development

• Support: Provides consultation and advice on regulatory requirements
• Participating Institute: NIDA
• To apply: Contact Marta DeSantis, Acting Branch Chief

Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (STTR)

• Support: Up to 2 years for Phase I and up to 3 years for Phase II may be requested. Budgets up to $1.0M total costs per year for Phase I and up to $1.5 total costs per year for Phase II may be requested.
• Participating Institute: NIAAA
• To apply: PAR-22-103 (UT1/UT2 - Clinical Trial Optional)

Investigational New Drug (IND)-enabling Development of Medications to Treat Alcohol Use disorder and Alcohol-related disorders (SBIR)

• Support: Up to 2 years for Phase I and up to 3 years for Phase II may be requested. Budgets up to $1.0M total costs per year for Phase I and up to $1.5 total costs per year for Phase II may be requested.
• Participating Institute: NIAAA
• To apply: PAR-22-102 (U43/U44 - Clinical Trial Optional)

Strategic Alliances for Medications Development to Treat Substance-Use Disorders

• Support: Up to 3 years of funding, includes discovery, development, and clinical trials. $3M per year with expectation of matching funds
• Participating Institute: NIDA
• To apply: PAR-19-318 (R01)

Grand Opportunities in Medications Development for Substance-Use Disorders

• Support: Up to 3 years of funding, milestone-driven, up to $5M per year
• Participating Institute: NIDA
• To apply: PAR-19-327 (U01)

Alzheimer's Drug-Development Program

• Support: Up to 5 years of funding, milestone-driven, up to $1M per year
• Participating Institute: NIA
• To apply: PAR-22-047 (U01)

Services

Services for Pharmacology

Epilepsy Therapy Screening Program (ETSP)

• Support: Screens compounds in animal seizure models
• To apply: Contact Brian Klein, Ph.D.

Addiction Treatment Discovery Program (ATDP)

• Support: Screens compounds in animal models of addiction
• To apply: Contact David White, Ph.D., (301) 443-8889

NIMH Psychoactive Drug Screening Program (PDSP)

• Support: Screens novel psychoactive compounds for pharmacological and functional activity at cloned human or rodent CNS receptors, channels, and transporters.
• To apply: Contact Jamie Driscoll, (301) 443-5288

Services for Toxicology

Bridging Interventional Development Gaps (BrIDGs)

• Support: Provides synthesis, formulation, pharmacokinetic and toxicology expertise and resources to its collaborators and is open to any disease.
• To apply: See the National Center for Advancing Translational Sciences (NCATS) for more information.

NIMH Toxicological Evaluation of Novel Ligands Program

• Support: Provides toxicology, safety, in vitro ADME, and pharmacokinetic assessment of promising, target-selective compounds for use as imaging ligands and novel psychoactive drugs.
• To apply: Contact Jamie Driscoll, (301) 443-5288

NIDA Toxicology Program

• Support: Provides IND-directed toxicology services for substance abuse indications.
• To apply: Contact Nathan M. Appel, Ph.D., (301) 443-8475

Services for Chemistry

Bridging Interventional Development Gaps (BrIDGs)

• Support: Provides chemical synthesis services, open to any disease
• To apply: See National Center for Advancing Translational Sciences (NCATS) for more information

NIDA Drug Supply Program

• Support: Provides chemicals and research probes that are either unavailable, difficult to obtain, or very expensive to buy to researchers, including marijuana plant materials, cannabinoids, opioids, stimulants, sedatives, hypnotics, standardized research E-Cigarettes and nicotine research c, etc. Also provides analytical services for the analysis of researchers’ experimental samples.
• To apply: Contact: Richard Kline, Ph.D., (301) 443-5280

NIMH Chemical Synthesis and Drug Supply Program

• Support: Synthesizes and distributes novel research chemicals, psychoactive drugs, and compounds unavailable from commercial sources. Also supports radiosynthesis, medicinal chemistry, and GMP synthesis for clinical studies.
• To apply: Contact Jamie Driscoll, (301) 443-5288

NIDA Chemistry and Pharmaceutics Branch

• Support: Medicinal chemistry, analytical chemistry, metabolism, pharmacokinetics and pharmacodynamics, pharmacogenetics and pharmaceutics/formulation development aimed at the design, evaluation and development of medications for the treatment of drug addiction
• To apply: Contact Rik Klein, (301)-827-5243, rkline@nida.nih.gov